Several strategies are currently being explored to target KRAS in cancer:
Direct Inhibitors: These are small molecules designed to directly bind to and inhibit mutant KRAS proteins. Sotorasib and Adagrasib are examples of drugs targeting the KRAS G12C mutation. Synthetic Lethality: This approach targets vulnerabilities created by KRAS mutations. For instance, inhibitors of the enzyme poly (ADP-ribose) polymerase (PARP) have shown promise in KRAS-mutant cancers. Immunotherapy: Leveraging the immune system to recognize and attack KRAS-mutant cells is another promising strategy. This includes CAR-T cell therapy and checkpoint inhibitors. Combination Therapies: Combining KRAS inhibitors with other treatments, such as MEK inhibitors or chemotherapy, can enhance the overall effectiveness and overcome resistance.
